clinical trial · NCT06081894
Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM
Cytokinetics·phase3·active not recruiting·n = 500
Symptomatic Non-Obstructive Hypertrophic CardiomyopathyAficamtenPlacebo
brief summary
This clinical trial will study the effects of aficamten (versus placebo) on the quality of life, exercise capacity, and clinical outcomes of patients with non-obstructive hypertrophic cardiomyopathy.
started
Aug 30, 2023
primary completion
Jun 1, 2026
completion
Sep 1, 2026
last updated
Feb 2, 2026
official title
A Phase 3, Multi-Center, Randomized, Double-Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol